Ultragenyx Pharmaceutical (RARE) Shares are Down -0.81%

Ultragenyx Pharmaceutical (RARE) has risen sharply, recording gains of 22.84% in the past 4 weeks. However, the stock has corrected -0.81% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 22.37% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

Ultragenyx Pharmaceutical Inc. is up 3.11% in the last 3-month period. Year-to-Date the stock performance stands at -41.17%. The stock has recorded a 20-day Moving Average of 4.26% and the 50-Day Moving Average is 14.67%.


Ultragenyx Pharmaceutical (NASDAQ:RARE): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $65.67 and $65.17 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $67.25. The buying momentum continued till the end and the stock did not give up its gains. It closed at $66.00, notching a gain of 0.24% for the day. The total traded volume was 338,647 . The stock had closed at $65.84 on the previous day.

Also, Piper Jaffray initiates coverage on Ultragenyx Pharmaceutical (NASDAQ:RARE). In the latest research report, Piper Jaffray announces the target price to $70 per share. According to the latest information available, the shares are now rated Overweight by the analysts at the agency. The rating by the firm was issued on July 7, 2016.

Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Its pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies. Its products are KRN23 (UX023), rhGUS (UX003), rhPPCA (UX004), Triheptanoin (UX007) and SA-ER (UX001). KRN23 is a fully human monoclonal antibody administered via subcutaneous injection. rhGUS is an intravenous (IV), enzyme replacement therapy for the treatment of mucopolysaccharidosis 7. rhPPCA is an enzyme replacement therapy for galactosialidosis. Triheptanoin is a medium odd-chain triglyceride of seven-carbon fatty acids. SA-ER is for the treatment of hereditary inclusion body myopathy (HIBM).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *